Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mesenchymal Stem Cells · 1 trial · 1 indication
Changes in meniscal volume over the course of the study as determined by MRI
| Arm | Type | Description |
|---|---|---|
| Chondrogen - dose 1 | ACTIVE_COMPARATOR | Chondrogen - 50 million cells |
| Chondrogen - dose 2 | ACTIVE_COMPARATOR | Chondrogen - 150 million cells |
| Vehicle Control | OTHER | Vehicle Control |
| Name | Type | Description |
|---|---|---|
| Mesenchymal Stem Cells | DRUG | - |
| Hyaluronan | DRUG | - |
Inclusion Criteria: * Age 18 to 60, inclusive * In need of medial meniscectomy * Normal axial alignment * Stable knee- previous ligament reconstruction, if stable * Removal of at least 50% of the affected portion of the medial meniscus * Intact articular cartilage in posterior meniscal weight-beari...
Mesenchymal Stem Cells is an investigational cell therapy being studied for recovery following partial medial meniscectomy, a surgical procedure on the knee. It is delivered by intra-articular injection directly into the joint. The drug is in Phase 1 clinical development and is not yet approved for any use.
Mesenchymal Stem Cells is being developed by Mesoblast Limited, a biopharmaceutical company publicly traded under the ticker MESO. The company is conducting clinical trials to evaluate the safety and efficacy of this cell therapy for patients recovering from partial medial meniscectomy.
Mesenchymal Stem Cells is in Phase 1 clinical development. A Phase I/II study has been completed, with a total of 60 participants enrolled. The drug remains investigational and has not received regulatory approval for any indication.
Mesenchymal Stem Cells has one completed clinical trial, NCT00225095, titled 'A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy.' This randomized, double-blind, active-controlled study enrolled 60 participants in the United States and evaluated the drug for recovery following partial medial meniscectomy.
Mesenchymal Stem Cells is administered by intra-articular injection, meaning it is injected directly into the knee joint. This route of delivery was used in the completed Phase I/II clinical trial for patients recovering from partial medial meniscectomy.